Company intelligence / Profile preview

萬欣生物科技

Sanmin Dist., Kaohsiung City, Taiwanmshasia.com ↗

Ownership: Private
Development stage: Other

Overview

Wanxin Biotech has over 30 years’ experience in the cross-strait beauty market. Since 2021, it has expanded into regenerative medicine with its own line of advanced peptide-based skincare products. The company positions itself as an industry leader in Taiwan’s regenerative medical aesthetics sector but does not appear to conduct clinical trials typical of pharmaceutical development; its results are commercial success and product adoption within the beauty industry rather than formal clinical endpoints.

Therapeutic areas: Dermatology
Modalities: PeptidesCosmetic biologics/Regenerative biomaterials
Industry: Non-Drug Biotech

Partnerships

Supported by international biomedical teams since 2021 expansion into regenerative medicine; specific partners not named publicly

Beyond the preview

Go deeper on 萬欣生物科技.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 萬欣生物科技.

Explore the full profile